s.hartmann

TL2 Moderator · Tampere

Contributes reviews on supplier material. Based in Tampere.

Joined 14 April 2025 · last posted 3d

95Posts here

2Topics

0Solutions

123Likes received

187Likes given

19Badges

120Days visited

1.1kPosts read

Recent activity

Full stream

Here for the analytics and not much else Replied, post #88 · Lounge › Introductions · 25 Jul 2026 · 0 likes Say hello. No question required. Introduce yourself if you want to give context for why you are here, or just introduce yourself because you like meeting people.
What is genuinely unknown about long-term amylin agonism Replied, post #80 · Compounds › Cagrilintide & amylin analogues · 24 Jul 2026 · 7 likes What is genuinely unknown about long-term amylin agonism: real-world response rates, whether effect is durable with continued use, whether satiety adaptation occurs…
Second pass at: Absence of evidence and evidence of absence Replied, post #51 · Research Methods › Statistics · 21 Jul 2026 · 10 likes On post #47 — agreed on the reasoning, with one qualification. Regression to the mean: if you select people with extreme values (very high or very low), their next…
Follow-up: How compounding permissions changed when supply normalised Replied, post #49 · Sourcing › Regulatory · 21 Jul 2026 · 30 likes Coming back to post #47, because the follow-up matters more than the original answer. Compounding and pharmacy rules: some jurisdictions allow a pharmacy to compound a…
Coming back to: A community side-effect dataset, with its response rate and biases Replied, post #98 · Data & Tools › Datasets · 19 Jul 2026 · 0 likes Using data in discussions: datasets are useful as reference points when someone claims something unusual. "I have not seen that reported in the data" is different from…
Why the cheapest option is often not the cheapest Replied, post #20 · Access › Pricing · 16 Jul 2026 · 13 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
Athletes in weight-category sports: a different risk calculus Replied, post #28 · Clinical › Special populations · 16 Jul 2026 · 0 likes post #27 answers the question as asked. The question underneath it is different. Pregnancy and planning: these compounds are not approved for use in pregnancy. Planning…
Coming back to: Why a preprint's supplementary material is often the best part Replied, post #101 · Evidence › Preprints · 9 Jul 2026 · 0 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
Reconstituting a multi-strength kit without mixing yourself up — what changed since Replied, post #36 · Practice › Reconstitution · 4 Jul 2026 · 26 likes Osmolarity and reconstitution: the osmolarity of the reconstituted solution affects comfort on injection. Isotonic solutions (close to blood osmolarity) are less…
Follow-up: Prior authorisation: what the criteria usually require Replied, post #52 · Access › Insurance & coverage · 3 Jul 2026 · 11 likes Tier placement and step therapy: some formularies place a medication on a higher tier or require you to fail cheaper alternatives before approving the one you want.…
Revisiting: Protein density versus volume when you cannot eat much Replied, post #25 · Nutrition & Training › Protein & intake · 2 Jul 2026 · 0 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #58 · Evidence › Journal club · 25 Jun 2026 · 1 like On post #54 — agreed on the reasoning, with one qualification. Two things before anyone answers the substance. First, the context in the first post is clear and…